The Incretin Landscape in 2026
Three compounds dominate the incretin-based metabolic research field in 2026: semaglutide (Novo Nordisk), tirzepatide (Eli Lilly), and retatrutide (Eli Lilly). Each targets a different combination of metabolic receptors, producing distinct pharmacological profiles. Understanding these differences is essential for researchers designing comparative studies or selecting compounds for specific metabolic pathway investigations.
Receptor Profiles
Semaglutide is a selective GLP-1 receptor agonist. It activates a single receptor pathway, primarily driving appetite suppression and glucose-dependent insulin secretion. Tirzepatide is a dual GIP/GLP-1 receptor agonist, adding GIP-mediated lipid metabolism enhancement to the GLP-1 backbone. Retatrutide is the only triple agonist, activating GIP, GLP-1, and Glucagon receptors simultaneously.
The addition of Glucagon receptor activity in Retatrutide introduces a mechanism not present in either competitor: direct stimulation of hepatic thermogenesis and adipose lipolysis, increasing resting energy expenditure independent of appetite suppression.
Efficacy Comparison
In Phase 3 trials, semaglutide at its highest approved dose achieved approximately 15% mean body weight reduction over 68 weeks (STEP trials). Tirzepatide achieved approximately 21% at its 15mg dose over 72 weeks (SURMOUNT-1). Retatrutide achieved 28.7% at the 12mg dose in TRIUMPH-4 — the highest figure recorded for any incretin-based compound in a controlled clinical trial.
The gap between tirzepatide and retatrutide is attributed almost entirely to the Glucagon receptor. Both compounds share GIP and GLP-1 activity. The addition of GCG-driven energy expenditure accounts for the approximately 7–8 percentage point differential.
Liver Fat Reduction
Hepatic steatosis (fatty liver) is a critical metabolic endpoint. Semaglutide produces modest liver fat reduction through weight loss alone. Tirzepatide shows moderate hepatic defatting. Retatrutide, through direct Glucagon-mediated lipolysis in hepatocytes, achieved greater than 86% liver fat reduction in Phase 2 substudies, with over 90% of MASLD subjects normalizing liver fat to below 5%.
Half-Life and Dosing
All three compounds are designed for once-weekly administration. Semaglutide has a half-life of approximately 7 days via albumin binding. Tirzepatide has a half-life of approximately 5 days via a C20 fatty diacid linker. Retatrutide has a half-life of approximately 6 days, also via C20 acylation. Dosing frequency is comparable across all three.
Research Implications
For researchers investigating single-receptor GLP-1 pathways, semaglutide remains the standard reference compound. For dual-receptor GIP/GLP-1 studies, tirzepatide is the reference. For triple-receptor studies or any investigation of Glucagon-mediated thermogenesis, hepatic defatting, or synergistic multi-receptor activation, Retatrutide is the only available compound.